Announced details
Therapeutic use for polycythemia, including polycythemia vera
Co-applicant for the use patent relating to PPMX-T003
U.S. patent allowance (title of invention: Drug for the Treatment of Polycythemia)
United States Patent and Trademark Office
Application No. 17/640,645 (international application No. PCT/JP2020/033561, filed on 4 September 2020). The patent will be registered upon payment of the registration fee following the allowance. The term is Not disclosed.
The receipt of this notice of allowance will have no impact on results for the current fiscal year. It is expected to contribute to an increase in corporate value over the medium to long term through future business development and other activities.
The company does not address Contract Value / Offering price.
United States Patent and Trademark Office
| Item | Details |
|---|---|
| Names of Products / Services Covered | PPMX-T003 (anti-transferrin receptor 1 antibody) |
| Counterparty | Juntendo Educational Corporation (co-applicant) |
| Relationship with the Company | Co-applicant for the use patent relating to PPMX-T003 |
| Applicable area | Therapeutic use for polycythemia, including polycythemia vera |
| Award/certification name | U.S. patent allowance (title of invention: Drug for the Treatment of Polycythemia) |
| Awarding / certifying body | United States Patent and Trademark Office |
| Registration number and expiry date | Application No. 17/640,645 (international application No. PCT/JP2020/033561, filed on 4 September 2020). The patent will be registered upon payment of the registration fee following the allowance. The term is Not disclosed. |
| Impact on Business Performance | The receipt of this notice of allowance will have no impact on results for the current fiscal year. It is expected to contribute to an increase in corporate value over the medium to long term through future business development and other activities. |
| Source | United States Patent and Trademark Office |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Following examination by the United States Patent and Trademark Office, the invention covered by the application was determined to merit the grant of patent rights. The receipt of this notice of allowance will have no impact on results for the current fiscal year, but is expected to contribute to an increase in corporate value over the medium to long term through future business development and other activities.